Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H14BrN3O |
Molecular Weight | 356.217 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)C(=C\C1=NC(Br)=CC=C1)\C#N)C2=CC=CC=C2
InChI
InChIKey=VFUAJMPDXIRPKO-LQELWAHVSA-N
InChI=1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1
WP1066 is a cell-permeable AG490 tyrphostin analog that effectively inhibits the phosphorylation of Janus kinase 2 (JAK2) and its downstream signal transducer and activator of transcription 3 (STAT3) in a dose- and time-dependent manner. As a result, WP1066 concentrations in the low micromolar range induced time- and dose-dependent antiproliferative and proapoptotic effects in cancer cells. WP1066 has been used in Phase I trial studying the treatment of melanoma, brain cancer, solid tumors, and central nervous system neoplasms.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18245540 |
2.3 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 μg/mL |
200 mg/kg single, oral dose: 200 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
WP 1066 plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
200 mg/kg single, oral dose: 200 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
WP 1066 plasma | Mus musculus population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01904123
6 mg/kg 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28739255
WP1066 was identified as a ceramide glucosyltransferase inhibitor by a screen of known small molecule inhibitors of various enzymes and protein factors. WP1066 inhibited the activity of ceramide glucosyltransferase with an IC50 of 7.2 uM, and that its action was independent of JAK/STAT3 pathway blockade. Moreover, the modes of inhibition of ceramide glucosyltransferase were uncompetitive with respect to both C6-NBD-ceramide and UDP-glucose.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
671018
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
63V8AIE65T
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY | |||
|
DB12679
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY | |||
|
11210478
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY | |||
|
C111042
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY | |||
|
DTXSID50235007
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY | |||
|
857064-38-1
Created by
admin on Sat Dec 16 01:15:10 GMT 2023 , Edited by admin on Sat Dec 16 01:15:10 GMT 2023
|
PRIMARY |
ACTIVE MOIETY